Warren calls on FTC to scrutinize Novo Holdings' $16.5B Catalent buyout – Fierce Pharma

by

QUORUMCALL//GPT:

BIG PICTURE
– Senator Elizabeth Warren is raising concerns over Novo Holdings’ proposed $165 billion acquisition of Catalent, a contract development and manufacturing organization (CDMO) that is a key player in the COVID-19 vaccine supply chain.

DETAILS
– Warren is questioning the potential antitrust implications of the deal, citing potential risks to the U.S. drug supply chain, especially in the midst of the ongoing pandemic.
– The senator has sent a letter to the Federal Trade Commission (FTC) urging it to scrutinize the acquisition, arguing that the deal could create a “pharmaceutical monopoly” and pose risks to drug affordability and accessibility.

IMPACT
– If the FTC were to take action based on Warren’s concerns, it could potentially put a halt to the deal, which is slated to be one of the largest acquisitions in the pharmaceutical industry.

TOPICS COVERED
– #Antitrust, #Pharmaceuticals, #COVID19, #VaccineSupplyChain

NOTE
– The source publication, Fierce Pharma, is a trade publication specializing in the business and regulatory aspects of the pharmaceutical industry. It is known for its coverage of drug development, manufacturing, and distribution.

Learn more — read the article in full here.

More Sen. Warren News

title words as hashtags: #Warren #calls #FTC #scrutinize #Novo #Holdings039 #16.5B #Catalent #buyout #Fierce #Pharma
source domain: www.fiercepharma.com
source link: https://www.fiercepharma.com/pharma/sen-warren-sets-sights-novo-holdings-proposed-165b-catalent-acquisition-deal-nears
matched content: Wednesday, Sen. Elizabeth Warren, D-Massachusetts, sent a … “Senator Warren's letter will make this investigation a key priority for the FTC.
author:
Visited 1 times, 1 visit(s) today
Close Search Window
Designed by Dannci